Shop by goal
Popular compounds
Research resources
Recently viewed
PT-141
Bremelanotide (PT-141) FDA-approved MC4R agonist for HSDD activates hypothalamic sexual arousal pathways via central melanocortin signaling. t½ 2.7 hours SC.
This strength is out of stock. Pick another strength, or check back soon — restocks are frequent.
From our community
What people say on Facebook
PRECISION. PURITY. PERFORMANCE.
Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.
Shop
Research
Support
Ways to Pay
Shop by goal
Shop by compound
Shop by region
Research use only - all claims made on this site are for testing and research use only. Purchasers must be 21 years of age or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io
PT-141
Compare pack sizes
Tap a pack to select it in the purchase panel above
Buy the 10-pack - save 61%/mg
Single vials ship as an add-on to a 10-vial pack - browse 10-vial packs
Lab-direct quality — full packs or single-vial samples
Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity . Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.
Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.
What It's Researched For
In plain terms, PT-141 (bremelanotide) is studied mainly for libido and sexual arousal, working through the brain rather than blood flow. Here is what that looks like across the research.
Libido & sexual desire
In clinical research it is investigated for low sexual desire, and the matching drug (Vyleesi) is FDA-approved for that use in premenopausal women.
Brain-driven arousal
Studied for switching on the brain circuits behind sexual interest, a completely different route from blood-flow pills like Viagra.
Arousal research in both sexes
Clinical research first explored it for erectile function in men before it was approved for desire in women, so the central mechanism is studied across both.
On-demand response window
Research looks at its use ahead of activity, with an effect window of several hours rather than a daily routine.
Overview
In short: PT-141 (bremelanotide, Vyleesi) is an FDA-approved MC4R agonist that drives sexual arousal through central hypothalamic signalling rather than peripheral vasodilation - a fundamentally different mechanism than PDE-5 inhibitors.
Key research facts
These points summarise lab themes, not human outcomes.
PT-141 is a cyclic heptapeptide that started life as an active metabolite of Melanotan-2. Researchers noticed that MT-2 produced notable arousal effects as a side effect of its broader melanocortin activity, and then tracked that signal to MC4R activation in the hypothalamus. They modified the molecule slightly - swapping an amide for a free carboxylic acid at the C-terminus - and ended up with a more selective compound that keeps the arousal effect and drops most of the pigmentation and appetite changes.
The practical consequence is a drug that works completely differently from Viagra or Cialis. PDE-5 inhibitors act peripherally - they help with the mechanics of erection but do nothing about desire. PT-141 works centrally, in the brain, activating the neural circuits that generate sexual interest and arousal in the first place.
The FDA approved PT-141 as Vyleesi in June 2019 for generalised hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first-in-class central-acting sexual dysfunction therapy. Supplied here as sterile lyophilised powder for in-vitro and preclinical research use.
Mechanism of Action
PT-141 activates MC4R in hypothalamic nuclei, triggering central sexual arousal circuits that operate upstream of any peripheral vasodilation pathway.
Pfaus et al. (Neuroscience and Biobehavioral Reviews, 2004) laid out the central-neurochemical framework for melanocortin-mediated sexual function. FDA prescribing information for Vyleesi (2019) reports SC bioavailability approximately 100%, Tmax ~1 h, t½ ~2.7 h (range 1.9-4.0 h), volume of distribution 25 L, clearance 6.5 L/h, 21% protein binding, and 64.8% renal / 22.8% fecal excretion. Despite the short plasma half-life, biological effects on sexual function persist 4-8 hours - longer than the circulating peptide - reflecting receptor residence time and downstream signalling.
Common Questions People Are Asking
What is PT-141?
PT-141 (bremelanotide) is a cyclic melanocortin-receptor agonist peptide that acts centrally on MC4R arousal pathways. It is the molecule approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. New-U's PT-141 is research-grade material supplied for laboratory use only - not the approved drug.
What does PT-141 do?
In research and clinical studies PT-141 activates hypothalamic MC4R circuits involved in sexual motivation/arousal - acting on the brain rather than on peripheral blood flow. These are findings for the molecule and imply no human effect.
What does PT-141 do for women?
The approved drug (bremelanotide / Vyleesi) is indicated for hypoactive sexual desire disorder in premenopausal women, acting on central MC4R arousal pathways. That is the clinical product; New-U supplies research-grade PT-141 strictly for laboratory research.
How long does PT-141 last?
Published pharmacology describes a short plasma half-life of about 2.7 hours, while the functional effect window reported in studies of the molecule spans roughly 4-8 hours - longer than the circulating peptide, reflecting receptor residence time. This is reported research context only - not human-use dosing guidance.
What does the research on PT-141 actually show?
The pivotal evidence is the RECONNECT program - two identical phase 3 trials in more than 1,200 premenopausal women with HSDD (Kingsberg et al., Obstetrics & Gynecology, 2019) - which reported statistically significant improvements in sexual desire and reductions in associated distress versus placebo, supporting the 2019 FDA approval of Vyleesi. Earlier research also studied the central MC4R mechanism in male erectile function. This is summarised published research about the molecule, not a human-use claim; New-U supplies research-grade PT-141 for laboratory research only.
Is PT-141 FDA approved?
The pharmaceutical bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. That approval applies to the finished prescription drug - NOT to research-grade material. New-U's PT-141 is an unapproved research powder supplied for laboratory research only.
How is PT-141 different from Viagra or Cialis?
PDE-5 inhibitors like Viagra work peripherally - they relax smooth muscle and improve blood flow to the genital tissue, which helps with the mechanics of erection. They do nothing about desire or arousal. PT-141 works centrally in the brain, activating hypothalamic MC4R circuits that generate sexual motivation. The two classes target completely different steps and can theoretically even be used together.
How is PT-141 different from Melanotan-2?
PT-141 is essentially an active metabolite of MT-2 with a free carboxylic acid at the C-terminus instead of an amide. That single change shifts selectivity toward MC4R-mediated arousal and away from the broader MC1/3/4/5 activity of MT-2 - keeping the sexual effects while reducing pigmentation, nausea, and facial flushing.
Why is nausea the most common side effect?
MC4R is expressed in multiple hypothalamic nuclei including the ones that control nausea and appetite, so central MC4R activation inevitably produces some nausea as a dose-dependent effect. In the Vyleesi clinical trials, around 40% of subjects experienced some nausea at the 1.75 mg dose - it is the predictable consequence of hitting MC4R centrally.
How should PT-141 be stored?
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The cyclic structure gives PT-141 good stability in solution within the normal peptide-handling window.
Where can I buy PT-141?
Right here - PT-141 is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.
How much does PT-141 cost?
PT-141 pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $350.
Is PT-141 third-party tested?
Yes. Every PT-141 batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.
How do I buy PT-141?
Add the PT-141 pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step. Every order ships with its batch Certificate of Analysis (COA).
What payment methods can I use to buy PT-141?
At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.
How fast is shipping, and do you ship worldwide?
Yes - we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.
Is it legal to buy PT-141?
In the United States, PT-141 is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.
Research use only - all claims made on this site are for testing and research use only.
Pharmacokinetics
Evidence Tier
Overall: Tier 1: Human clinical
Bremelanotide is FDA-approved as Vyleesi on the strength of pivotal phase 3 trials, so the molecule itself is Tier 1 for HSDD. The research-grade material supplied here is NOT the approved drug (Vyleesi) - it is unapproved laboratory material.
Tier 1 · Human clinical
Certificates, databases & peer-reviewed sources
Last reviewed: 16 June 2026 · New-U Research Compounds
Key Characteristics
Specifications
About PT-141 (Bremelanotide / Vyleesi): Central Arousal & MC4R Research Guide
PT-141 is the first sexual-dysfunction drug to act centrally rather than peripherally, and that distinction is the whole point of the molecule. The entire first generation of approved treatments - sildenafil, tadalafil, vardenafil, avanafil - works through phosphodiesterase-5 inhibition, which relaxes smooth muscle and improves penile blood flow. None of them do anything about desire or central arousal. PT-141 comes from a completely different pharmacological direction.
The mechanism grew out of the Melanotan-2 program. Researchers noticed that MT-2 produced distinct arousal effects alongside its pigmentation and appetite activity, traced that signal to MC4R activation in the hypothalamus, and tuned the molecule to preserve the MC4R arm while reducing the other melanocortin effects. That work produced bremelanotide. Its FDA approval rested on two identical phase 3 trials (the RECONNECT program; Kingsberg et al., Obstetrics & Gynecology, 2019) in more than 1,200 premenopausal women with HSDD, which reported statistically significant improvements in sexual desire and reductions in associated distress versus placebo. Palatin Technologies brought it through approval as Vyleesi in 2019, the first central-acting, on-demand treatment for generalised HSDD.
New-U Research Compounds supplies PT-141 as a research-grade lyophilised powder at >99% HPLC purity, verified by independent third-party labs. All material is strictly for in-vitro and preclinical laboratory research use and is not a substitute for prescribed Vyleesi. Nothing on this page is medical advice. The FDA label for the finished drug caps administration at one dose per 24 hours and no more than eight doses per month for safety reasons.
Customer Reviews
No customer reviews yet - be the first to share your experience.
More in Tanning / Libido
PT-141 vs related Tanning / Libido compounds
Descriptive catalog comparison for research sourcing decisions - not dosing guidance.